123.03
price up icon0.32%   0.39
after-market Dopo l'orario di chiusura: 123.03
loading
Precedente Chiudi:
$122.64
Aprire:
$122.88
Volume 24 ore:
1.02M
Relative Volume:
0.69
Capitalizzazione di mercato:
$12.18B
Reddito:
$2.41B
Utile/perdita netta:
$305.80M
Rapporto P/E:
41.71
EPS:
2.95
Flusso di cassa netto:
$492.20M
1 W Prestazione:
+2.05%
1M Prestazione:
+15.56%
6M Prestazione:
-2.81%
1 anno Prestazione:
-12.42%
Intervallo 1D:
Value
$122.47
$124.30
Intervallo di 1 settimana:
Value
$117.59
$124.30
Portata 52W:
Value
$84.23
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Nome
Neurocrine Biosciences Inc
Name
Telefono
(858) 617-7600
Name
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Dipendente
1,800
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
NBIX's Discussions on Twitter

Confronta NBIX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
123.03 11.93B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.25 49.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
165.40 71.87B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.80 4.35M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.59 44.73B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
18.15 18.98B 16.54B -1.64B 749.00M -1.45

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-15 Aggiornamento Needham Hold → Buy
2025-04-14 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2025-02-11 Iniziato Deutsche Bank Hold
2024-10-10 Ripresa Raymond James Outperform
2024-08-29 Aggiornamento Piper Sandler Neutral → Overweight
2024-04-24 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-12-13 Ripresa Citigroup Neutral
2023-12-12 Iniziato Deutsche Bank Buy
2023-10-24 Ripresa Cantor Fitzgerald Overweight
2023-08-21 Reiterato Mizuho Neutral
2023-07-24 Aggiornamento SVB Securities Market Perform → Outperform
2023-07-06 Aggiornamento BMO Capital Markets Underperform → Market Perform
2023-05-04 Aggiornamento Guggenheim Neutral → Buy
2023-03-30 Aggiornamento Canaccord Genuity Hold → Buy
2023-03-03 Aggiornamento Evercore ISI In-line → Outperform
2023-02-03 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-11-14 Downgrade Evercore ISI Outperform → In-line
2022-10-11 Iniziato UBS Buy
2022-09-26 Iniziato Wells Fargo Equal Weight
2022-06-06 Ripresa Jefferies Buy
2022-03-03 Downgrade Piper Sandler Overweight → Neutral
2022-02-25 Aggiornamento Goldman Neutral → Buy
2022-01-18 Downgrade RBC Capital Mkts Outperform → Sector Perform
2021-11-19 Iniziato BMO Capital Markets Underperform
2021-11-17 Aggiornamento JP Morgan Neutral → Overweight
2021-10-14 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-09-23 Ripresa Needham Hold
2021-08-06 Downgrade Canaccord Genuity Buy → Hold
2021-05-18 Ripresa Goldman Neutral
2021-05-06 Aggiornamento Barclays Equal Weight → Overweight
2021-02-02 Iniziato Raymond James Outperform
2020-09-30 Iniziato The Benchmark Company Hold
2020-08-04 Downgrade JP Morgan Overweight → Neutral
2020-06-29 Downgrade Goldman Buy → Neutral
2020-06-09 Iniziato Wedbush Outperform
2020-03-06 Iniziato Citigroup Buy
2020-02-27 Iniziato Barclays Equal Weight
2020-02-24 Iniziato William Blair Outperform
2020-02-06 Iniziato Mizuho Neutral
2020-02-05 Reiterato H.C. Wainwright Buy
2019-12-13 Downgrade Credit Suisse Outperform → Neutral
2019-08-07 Iniziato RBC Capital Mkts Outperform
2019-07-16 Iniziato Oppenheimer Outperform
2019-06-05 Iniziato Guggenheim Neutral
2019-05-21 Iniziato Credit Suisse Outperform
2019-04-22 Aggiornamento JP Morgan Neutral → Overweight
2019-04-12 Iniziato Evercore ISI Outperform
2019-02-06 Reiterato BofA/Merrill Buy
2019-01-23 Downgrade JP Morgan Overweight → Neutral
2018-12-13 Iniziato Goldman Buy
2018-11-21 Iniziato Canaccord Genuity Buy
Mostra tutto

Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie

pulisher
07:45 AM

Nxera Pharma Notes Neurocrine Biosciences Presents New - GlobeNewswire

07:45 AM
pulisher
07:43 AM

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - GlobeNewswire Inc.

07:43 AM
pulisher
04:21 AM

Neurocrine reports positive Phase 2 schizophrenia study results - Investing.com

04:21 AM
pulisher
04:14 AM

Neurocrine reports positive Phase 2 schizophrenia study results By Investing.com - Investing.com UK

04:14 AM
pulisher
04:05 AM

Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - Yahoo Finance

04:05 AM
pulisher
May 25, 2025

Neurocrine Biosciences’ SWOT analysis: stock’s resilience amid market challenges - Investing.com Australia

May 25, 2025
pulisher
May 24, 2025

How to Take Advantage of moves in (NBIX) - news.stocktradersdaily.com

May 24, 2025
pulisher
May 23, 2025

Insider Decision Making Waves At Neurocrine Biosciences: CHARLES KEVIN GORMAN Exercises Options, Realizing $0 - Nasdaq

May 23, 2025
pulisher
May 20, 2025

Neurocrine at RBC Conference: Growth and Strategic Insights - Investing.com

May 20, 2025
pulisher
May 20, 2025

Transcript : Neurocrine Biosciences, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 11 - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Tourette Syndrome Treatment Market Detailed Analysis - openPR.com

May 20, 2025
pulisher
May 17, 2025

Neurocrine Biosciences (NBIX) Shares Positive Results from Pedia - GuruFocus

May 17, 2025
pulisher
May 16, 2025

Neurocrine reports quality of life gains in tardive dyskinesia study By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 16, 2025

Neurocrine Presents Encouraging New Data From Phase 4 Study Of Ingrezza In Tardive Dyskinesia - Nasdaq

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports lasting benefits of CRENESSITY in CAH study By Investing.com - Investing.com India

May 16, 2025
pulisher
May 16, 2025

Neurocrine Biosciences Says Tardive Dyskinesia Treatment Improves Functional, Quality of Life Measures - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports quality of life gains in tardive dyskinesia study - Investing.com

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports progress for CAH drug as Voyager partnership shifts - The Pharma Letter

May 16, 2025
pulisher
May 16, 2025

Neurocrine reports lasting benefits of CRENESSITY in CAH study - Investing.com

May 16, 2025
pulisher
May 16, 2025

Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting - PR Newswire

May 16, 2025
pulisher
May 16, 2025

Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia - WV News

May 16, 2025
pulisher
May 16, 2025

Groundbreaking One-Year Data: New Drug Reduces Steroid Use in Children with Rare Hormone Disorder - Stock Titan

May 16, 2025
pulisher
May 15, 2025

Neurocrine Biosciences, Inc. (NBIX): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

90% Success Rate: CRENESSITY Shows Breakthrough Results in Congenital Adrenal Hyperplasia | NBIX Stock News - Stock Titan

May 15, 2025
pulisher
May 15, 2025

Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont) - PR Newswire

May 15, 2025
pulisher
May 14, 2025

Neurocrine (NBIX) Highlights Risks of High Glucocorticoid Doses in CAH Patients | NBIX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia - PR Newswire

May 14, 2025
pulisher
May 14, 2025

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results - Longview News-Journal

May 14, 2025
pulisher
May 14, 2025

New Research Reveals Dangerous Side Effects of High-Dose Steroids in CAH Treatment: What Doctors Need to Know - Stock Titan

May 14, 2025
pulisher
May 13, 2025

15 Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Neurocrine at BofA Conference: Strategic Moves and Market Challenges - Investing.com

May 13, 2025
pulisher
May 13, 2025

Learn to Evaluate (NBIX) using the Charts - news.stocktradersdaily.com

May 13, 2025
pulisher
May 13, 2025

Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin’s Midcap Stock Picks with Huge Upside Potential - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Neurocrine Biosciences To Present BofA Securities 2025 Health Care Conference; Webcast At 2:20 PM ET - Nasdaq

May 13, 2025
pulisher
May 12, 2025

Crinecerfont Reduces Steroid Use for Pediatric CAH in Phase 3 Analysis - HCPLive

May 12, 2025
pulisher
May 12, 2025

Cognitive Impairment Associated with Schizophrenia Pipeline - openPR.com

May 12, 2025
pulisher
May 12, 2025

Cognitive Impairment Associated with Schizophrenia Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Cyclerion Therapeutics, Biogen, Neurocrine - Barchart.com

May 12, 2025
pulisher
May 12, 2025

Investors Can Find Comfort In Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Quality - Yahoo Finance

May 12, 2025
pulisher
May 11, 2025

Earnings Tell The Story For Neurocrine Biosciences, Inc. (NASDAQ:NBIX) As Its Stock Soars 27% - simplywall.st

May 11, 2025
pulisher
May 10, 2025

Wedbush Lifts Earnings Estimates for Neurocrine Biosciences - Defense World

May 10, 2025
pulisher
May 09, 2025

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma - insights.citeline.com

May 09, 2025
pulisher
May 09, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $160.00 - Defense World

May 09, 2025
pulisher
May 09, 2025

Wedbush Forecasts Lower Earnings for Neurocrine Biosciences - Defense World

May 09, 2025
pulisher
May 09, 2025

Neurocrine Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

May 09, 2025
pulisher
May 08, 2025

Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Neurocrine leans on singer Carnie Wilson for tardive dyskinesia push - Medical Marketing and Media

May 08, 2025
pulisher
May 08, 2025

Neurocrine Reports Late Stage Data Of Crenessity - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Neurocrine Biosciences, Inc. Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst?? Pediatric Study - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Neurocrine surges 13% on Q1 revenue beat, reaffirmed 2025 guidance - MSN

May 08, 2025
pulisher
May 07, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 07, 2025
pulisher
May 07, 2025

Cantor Fitzgerald maintains Overweight on Neurocrine Bio, $170 target - Investing.com Australia

May 07, 2025

Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_specialty_generic RDY
$14.56
price down icon 1.29%
drug_manufacturers_specialty_generic HCM
$13.23
price down icon 1.34%
$315.64
price up icon 0.25%
$8.59
price down icon 0.12%
$18.15
price up icon 2.48%
Capitalizzazione:     |  Volume (24 ore):